Converge Bio, a Boston- and Tel Aviv-based startup, has raised $25 million in a Series A funding round led by Bessemer Venture Partners to advance its generative AI platform for drug discovery. The financing brings the company’s total funding to $30 million and includes participation from TLV Partners, Vintage Investment Partners, and executives from Meta, OpenAI, and Wiz. Founded in 2023, Converge Bio specializes in leveraging generative models trained directly on molecular data, including DNA, RNA, and protein sequences. This approach enables pharmaceutical and biotech firms to accelerate drug development across multiple stages such as target discovery, antibody design, and protein manufacturing optimization.
Converge Bio’s platform integrates generative and predictive AI models to filter and optimize new molecules, reducing risk and improving outcomes for its clients. According to CEO and co-founder Dov Gertz, the system is designed to fit seamlessly into existing scientific workflows, allowing biologists to produce actionable insights without the need for coding or complex infrastructure. The company has already attracted over a dozen clients in the pharmaceutical and biotech sectors, reflecting growing industry demand for AI-driven drug development tools.
The $25 million funding will be used to expand the platform’s capabilities, scale the team, and deepen partnerships within the life sciences industry. Converge Bio’s innovative use of generative AI exemplifies a broader trend in life sciences to harness advanced AI systems to speed drug discovery and improve pharmaceutical innovation.
